Johnson & Johnson Plans Montgomery County, Pennsylvania, Manufacturing Operations
02/27/2026
The investment will include the construction of a new cell therapy manufacturing facility, located in Lower Gwynedd Township, which will be operated by the company’s subsidiary Janssen Biotech and will directly support the production of medicines for cancer, immune-mediated, and neurological diseases.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
The project is being supported by a funding proposal from DCED for up to $12 million in tax credits through the Qualified Manufacturing Innovation and Reinvestment Deduction (QMIRD) program, up to $2 million in tax credits through the Manufacturing Tax Credit (MTC) program, a $15 million grant through the PA SITES (Pennsylvania Strategic Investments to Enhance Sites) program, and a $10 million Pennsylvania First grant.
The state has also committed to providing a Redevelopment Assistance Capital Program award of up to $2.5 million to a local community college and/or technical school to help create a workforce development training program that would serve as a talent pipeline for the company in Montgomery County. Johnson & Johnson is also receiving assistance through Pennsylvania’s Office of Transformation and Opportunity on the project via the PA Permit Fast Track Program.
“We value Johnson & Johnson’s long-time partnership here in Pennsylvania, and its decision to reinvest in Montgomery County is another huge win for the Commonwealth – further expanding our life science ecosystem, while also producing life-saving medications for people undergoing cancer treatment, ” noted Pennsylvania Department of Community & Economic Development (DCED) Secretary Rick Siger. “This announcement also sends a clear message that Pennsylvania is competing — and winning — when it comes to attracting world-class life sciences companies, growing high-quality jobs, and driving long-term economic growth across the Commonwealth. We will continue to support projects like this by making investments that keep our economic momentum going and spur our innovation economy.”
Johnson & Johnson currently operates ten facilities across Pennsylvania.
Project Announcements
Japan-Based TOCALO Plans Chandler, Arizona, Operations
04/17/2026
Dakota Bodies Expands Liberty, Missouri, Operations
04/17/2026
Linde Plans Garysburg, North Carolina, Air Separation Operations
04/17/2026
Netherlands-Based Signature Foods USA Plans Easley, South Carolina, Manufacturing Operations
04/16/2026
Lumber Liquidators Plans Lawrenceburg, Tennessee, Headquarters Operations
04/16/2026
Canada-Based Bioriginal Food & Science Plans Grand Junction, Colorado, Operations
04/15/2026
Most Read
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Where Workforce Capacity Is Being Built — and Where It’s Being Deployed
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026